FDA Novel Drug Approval: Zycubo for Menkes Disease

The FDA has approved copper histidinate (Zycubo) for the treatment of Menkes disease, addressing a long-standing unmet need in this rare genetic neurological condition.

The U.S. Food and Drug Administration (FDA) has approved copper histidinate (Zycubo) for the treatment of Menkes disease, a rare genetic neurological condition.

This decision addresses a long-standing unmet medical need, marking the first targeted therapy for patients with this life-limiting disorder.

Alert Type	Drug Approval
Drug Name	Zycubo
Indication	Menkes disease
Therapy Area(s)	Neurology
Geography	US (FDA)
What Changed	FDA approved Zycubo (copper histidinate) for treatment of Menkes disease on 12/1/2026. This provides the first targeted therapy for this rare genetic disorder.
Clinical Relevance	Offers a potentially life-altering therapy for patients with Menkes disease, addressing a previously unmet medical need.
Source Link	https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
Date	12th Jan 2026
Status	Draft
Notes	Pediatric population; post-marketing studies may be ongoing.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com